Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
November 14, 2024 16:05 ET
|
Avenue Therapeutics
MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
August 09, 2024 16:05 ET
|
Avenue Therapeutics
- Last patient visit complete in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data anticipated in second half of 2024 – - Raised $4.4 million in gross proceeds...
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 15, 2024 08:30 ET
|
Avenue Therapeutics
– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue”...
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
March 18, 2024 16:05 ET
|
Avenue Therapeutics
- Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 - - Presented positive BAER-101 preclinical...
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
March 11, 2024 08:00 ET
|
Avenue Therapeutics
BAER-101 demonstrated full suppression of seizure activity in SynapCell's GAERS model of absence epilepsy, a proven indicator of efficacy in anti-seizure drug development with high predictability of...
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
February 22, 2024 08:30 ET
|
Avenue Therapeutics
MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
December 01, 2023 08:30 ET
|
Avenue Therapeutics
MIAMI, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
November 13, 2023 16:05 ET
|
Avenue Therapeutics
- Phase 1b/2a clinical trial of AJ201 remains on track to report topline data in second quarter of 2024 - - Positive BAER-101 preclinical data accepted for presentation at American Epilepsy Society...
Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study
August 01, 2023 08:30 ET
|
Avenue Therapeutics
MIAMI, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
May 12, 2023 08:30 ET
|
Avenue Therapeutics
MIAMI, May 12, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...